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Abstract
Recent years have seen major developments in psychother-
apy research that suggest the need to address critical meth-
odological issues. These recommendations, developed by 
an international group of researchers, do not replace those 
for randomized controlled trials, but rather supplement 
strategies that need to be taken into account when consider-
ing psychological treatments. The limitations of traditional 
taxonomy and assessment methods are outlined, with sug-
gestions for consideration of staging methods. Active psy-
chotherapy control groups are recommended, and adaptive 
and dismantling study designs offer important opportuni-
ties. The treatments that are used, and particularly their spe-
cific ingredients, need to be described in detail for both the 
experimental and the control groups. Assessment should be 
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performed blind before and after treatment and at long-
term follow-up. A combination of observer- and self-rated 
measures is recommended. Side effects of psychotherapy 
should be evaluated using appropriate methods. Finally, the 
number of participants who deteriorate after treatment 
should be noted according to the methods that were used 
to define response or remission. © 2018 S. Karger AG, Basel
Research in psychotherapy is crucial to test and pro-
vide support for psychological treatments which may im-
prove public health and reduce the burden of mental ill-
ness and behavioral problems [1]. Psychotherapeutic 
strategies may also have potential to improve psycholog-
ical coping, quality of life, illness behavior, and affective 
components of medical illness [2]. A clinical response af-
ter treatment is not synonymous with an effect that can 
be attributed to psychotherapy. The latter can only be ac-
curately estimated with reference to an appropriate con-
trol group. The randomized controlled trials (RCT) play 
the most important role in this process, even though also 
other forms of investigation may yield valuable informa-
tion [3–9]. The methodology for psychological interven-
tions of trials has been discussed in the literature [3, 5, 6, 
8, 9–13]. In Psychotherapy and Psychosomatics, specific 
reference to the selection and design of control condi-
tions has been made [14]. However, in recent years there 
have been important developments that suggest the need 
to address critical methodological issues. These recom-
mendations do not replace those that are operational for 
RCT [15], with particular reference to the CONSORT 
statement for nonpharmacological treatments [11], but 
rather supplement issues that need to be taken into ac-
count for an updated consideration of clinical trials con-
cerned with the efficacy of psychological interventions. 
We will not discuss designs that aim to identify outcome 
predictors, process variables, and qualitative studies. 
Inclusion Criteria
Diagnostic criteria have been developed in psychiatry 
and clinical psychology to improve the interrater reliabil-
ity of diagnostic assessments [16]. These criteria are par-
ticularly helpful in setting a threshold for conditions wor-
thy of clinical attention and, not surprisingly, clinical 
studies concerned with psychological interventions and/
or pharmacotherapy are generally based on DSM nomen-
clature. However, questions may be raised about the ef-
fectiveness of diagnostic criteria in yielding relatively ho-
mogeneous conditions in terms of severity and course 
of illness that are amenable to be tested by RCT [12]. As 
an addition to diagnostic categorical approaches, net-
work analysis may yield valuable insights into changes in 
patterns of symptoms and signs in psychotherapy trials 
[17–18].
The standard RCT design in medicine is still based on 
the acute disease model and ideally evaluates therapeutic 
effects in untreated patients who have a recent acute onset 
of their disorders. This is in sharp contrast with the fact 
that previous treatments may have actually modified the 
course and responsiveness of the individual patient [19–
22]. Any type of treatment, such as long-term use of psy-
chotropic medications, may increase the risk of experi-
encing additional health problems that do not necessarily 
subside with discontinuation of the medication and mod-
ify responsiveness to subsequent treatments. The term 
“iatrogenic comorbidity” refers to unfavorable modifica-
tions in the course, characteristics, and responsiveness of 
an illness that may be related to treatments previously 
administered [21]. Such vulnerabilities may occur during 
treatment administration (whether pharmacotherapy or 
psychotherapy) and/or manifest themselves after its dis-
continuation. The changes can be persistent and not lim-
ited to a short phase, such as in the case of persistent post-
withdrawal disorders after discontinuation of psychotro-
pic medications, and cannot be subsumed under the 
generic rubrics of adverse events or side effects [23]. Pa-
tients are generally included in a trial irrespectively of 
previous treatments (the so-called “nowhere patients”), 
even though these features may affect its outcome [20]. 
Meta-analyses of these groups of patients may amplify the 
heterogeneous nature of the clinical populations [24], 
particularly if the randomization process does not take 
these variables into account. 
Staging offers important opportunities to incorporate 
a patient’s history into the assignment to randomization. 
Staging methods have been developed for unipolar de-
pression, bipolar disorder, panic disorder, schizophrenia, 
eating disorders, and alcohol use disorders [25, 26]. This 
differs from the conventional diagnostic practice in that 
it defines not only the extent of progression of a disorder 
at a particular point in time but also where a person is 
currently standing along the continuum of the course of 
illness, including the previous response to treatment. 
Staging has an important role in planning psychothera-
peutic interventions in patients with mental disorders 
[27], particularly in the sequential model where psycho-
therapeutic intervention is applied to the residual phase 
after pharmacotherapy of depression [28, 29]. Further, 
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staging allows classification of previous responses to 
treatment (including psychotherapy), such as resistance 
or loss of a clinical effect [26, 30].
In addition to the inclusion criteria, other important 
points for the validity of a psychotherapy study are how 
the recruitment of patients takes place and how represen-
tative the sample examined is.
Study Design and Choice of the Control Group
Parallel group designs are the most widely used mo-
dalities of investigation of psychological interventions. 
Since the effects of a psychotherapeutic approach cannot 
be withdrawn or switched to attention-placebo, crossover 
designs entail major methodological problems. The de-
sign of a control group in a parallel controlled study very 
much depends on the purposes of the study. The most 
frequently used models are as follows.
Comparison between Experimental and Control 
Psychotherapy
This is the classic model of RCT in psychological in-
terventions [14]. In psychotherapy research, the no-treat-
ment control condition was soon found to be clearly in-
adequate, since it does not incorporate any of the ingre-
dients that are subsumed under the placebo effect [31]. 
The waiting list control (WLC) does not provide most of 
the variables which occur within a psychotherapeutic 
process, such as establishing a therapeutic relationship or 
encouragement. The WLC may be followed by the ex-
perimental treatment after a certain time lag (the cross-
over variant). Another option is the minimal attention 
control group, which offers the people on the WLC a min-
imum of contact by the researcher and/or monitoring of 
symptoms and well-being. Even though it may provide a 
certain control for the natural course of the condition and 
for patient’s expectations, the WLC may overestimate the 
true effects of an intervention [32] and is likely to be in-
adequate in view of the previous treatments that may have 
been experienced. Further, the illness may change during 
the waiting period. The WLC may thus be suitable for 
preliminary testing of an experimental procedure and for 
pilot studies. 
Comparison between Experimental Psychotherapy 
and Treatment as Usual
Routine interventions provided by clinicians in the 
settings from which participants are recruited provide 
another commonly used form of control [14]. Obviously, 
this type of control does not allow establishment of 
whether any significant difference – that was yielded by 
the addition of psychotherapy to treatment as usual 
(TAU) or care as usual – was actually due to some spe-
cific treatment ingredients, introduced by the experimen-
tal procedure, or to nonspecific factors, such as attention 
and opportunity for disclosure [2, 33, 34]. Further, TAU 
is seldom manualized, monitored, or supervised and may 
be anything but usual [35]. The value of TAU lies in pro-
viding a demonstration of the clinical value of an ap-
proach once its specific features have been demonstrated 
against other forms of control groups. Considering the 
growing role of psychotropic medications in the manage-
ment of patients, iatrogenic comorbidity is likely to con-
siderably affect the outcomes of TAU in both experimen-
tal and control conditions [21].
Comparison between Experimental Psychotherapy 
and Nonspecific Treatment Component Control 
Group
An experimental form of psychological intervention 
may be compared to an attention placebo group. Placebo 
effects are often attributed to clinical interactions and 
contextual factors that affect the expectations of the pa-
tient about the treatment and result in symptom changes 
[36]. There are many forms of attention placebo control 
groups. In “clinical management” (CM), a control group 
receives the same amount of time and attention from a 
professional figure than the experimental group, but 
without any specific interventions such as exposure, a 
structured diary, or cognitive restructuring. It applies 
psychological understanding to the management of an 
individual patient, identifying current problems and pro-
viding opportunities for disclosure. It may be associated 
with medication monitoring [37, 38], but its primary fo-
cus may also be unrelated to pharmacological treatment 
[39–42]. Since CM provides the nonspecific ingredients 
of the psychotherapeutic approach, significant differenc-
es between an experimental treatment and CM are likely 
to reflect specific ingredients entailed by the experimental 
approach, unlike what takes place with TAU or WLC. CM 
should be differentiated from nonspecific factor compo-
nent control [6], where patients are informed only about 
treatments available or self-aid options and psychothera-
peutic management is missing.
Attention placebo control groups may suffer from low 
acceptance by participants, resulting in unbalanced and/
or heightened dropout rates [43].
Another option is to submit the control group to a 
treatment, which was found to be devoid of therapeutic 
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effectiveness in other studies. For instance, in the Lon-
don-Toronto study, exposure treatment was compared to 
relaxation, a treatment modality that was found to be in-
effective in panic disorder and could thus act as psycho-
logical placebo [44].
Comparison between Experimental Psychotherapy 
and Other Treatments
Another modality is to compare a psychotherapeutic 
approach to another treatment that was found to be effec-
tive in other studies, whether pharmacotherapy or psy-
chotherapy. The problem with this type of comparison is 
that we do not know whether in that specific situation the 
gold standard (whether pharmacotherapy or psychother-
apy) would be superior to placebo or not. Only a 3- or 
4-arm design including pharmacological and/or psycho-
logical placebo [44] could solve this problem.
The comparison of 2 active psychological treatments 
may lead to nonsignificant differences in statistical tests. 
Although the methods for noninferiority trials have been 
refined, these approaches may have a bias in favor of (er-
roneous) noninferiority conclusions [45].
Adaptive Designs
An adaptive intervention is a multistage process that 
is based on the patient’s characteristics and intermediate 
outcomes collected during an intervention, such as the 
patient’s response after the first line of treatment [46]. 
The Sequential Multiple Assignment Randomized Trial 
(SMART) involves multiple intervention stages; each 
stage corresponds to one of the critical decisions and the 
participant is randomly reassigned to one of the interven-
tion options [46]. Examples are adaptive interventions 
that followed nonresponse to initial treatment (whether 
pharmacotherapy or psychotherapy or both) in mood 
[47–49] and anxiety disorders [50–52]. The conceptual 
assumption is that after testing a standard treatment in a 
group of patients we are left with a fairly homogeneous 
group characterized by resistance. Actually, nonresponse 
may include a very wide range of explanations (inade-
quate treatment in terms of indication, dosage, or dura-
tion; the occurrence of side effects prevailing over bene-
fits; partial compliance; previous exposure to that spe-
cific treatment; psychosocial events and/or physical 
health problems intervening during the trial; problems in 
the patient-therapist relationship; and modifications in 
the patient’s lifestyle and illness behavior). Various forms 
of tolerance (e.g., resistance upon rechallenge with the 
same medication that yielded a response, and loss of clin-
ical effect) and dependence may occur with pharmaco-
logical treatment and are likely to affect the treatment re-
sponse [22, 31, 53]. Nonresponse thus encompasses very 
heterogeneous features. Very seldom, however, such clin-
ical events are considered for inclusion of patients in a 
trial. 
Dismantling Studies
Treatment outcome in medicine is the cumulative re-
sult of the interaction of several classes of variables with 
a selected treatment, i.e., living conditions, patient char-
acteristics, self-management, illness characteristics, and 
previous treatments, as well as treatment setting [36]. A 
psychotherapeutic approach is likely to include multiple 
treatment ingredients [10, 12, 14]. As a result, disman-
tling designs may determine whether a specific treatment 
component may yield additional value to the treatment 
package. They include both studies in which full and par-
tial treatment packages are compared and those in which 
a given component is added to an existing therapy [54]. 
For instance, classic studies performed in the seventies 
and eighties in anxiety disorders demonstrated the re-
dundant nature of relaxation and therapist-aided expo-
sure compared to homework exposure in phobic disor-
ders [55]. Other examples of dismantling design may in-
volve the role of meditation in mindfulness-based 
cognitive therapy [56] or the sequential use of 2 different 
psychotherapeutic strategies compared to a single psy-
chotherapeutic technique [57]. Dismantling designs may 
assess the relative impact of including, or even targeting, 
family members in psychotherapy with children and ado-
lescents. Alternative designs that could yield valuable in-
sights may involve microtrials/case series designs. How-
ever, dismantling or specific-factor component control 
studies may present problems regarding sample size and 
statistical power [58].
Interaction of Experimental Psychotherapy with 
Pharmacotherapy
There are 4 models of interaction: (1) addition (the 
effect of 2 interactions combined equals the sum of their 
individual effects), (2) potentiation (the effect of 2 inter-
ventions combined is greater than the sum of their indi-
vidual effects), (3) inhibition (the effect of 2 interven-
tions combined is less than each individual effect), and 
(4) reciprocation (the effect of 2 interventions combined 
equals the individual effect of the more potent interven-
tion) [59]. Even though most of the studies are compat-
ible with the additive and reciprocal models of interac-
tion, also inhibitory effects can occur [60–63]. Adequate 
study of the interaction between psychotherapy and 
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pharmacotherapy requires the use of both an active med-
ication and placebo. For instance, one of the most influ-
ential efficacy studies of antidepressant medications in 
adolescents, the Treatment for Adolescents with Depres-
sion Study (TADS) [64], included a comparison between 
cognitive behavioral therapy alone, fluoxetine, placebo, 
and the combination of fluoxetine and cognitive behav-
ioral therapy. There was not, however, a placebo associ-
ated with the cognitive behavioral therapy group, a deci-
sion that favored the pharmacotherapy/psychotherapy 
combination and excluded the possibility of an inhibi-
tory effect (with psychotherapy plus placebo being sig-
nificantly superior to pharmacotherapy plus psychother-
apy), as was found to be the case in the London-Toronto 
study where both alprazolam and placebo were investi-
gated [44].
Description of Treatment Components
Psychological interventions are usually complex and 
involve several components, each of which may influence 
the estimated treatment effect [10, 11]. Regardless of the 
study design, it appears to be important that all potential 
treatment ingredients that were found to yield effects in 
controlled trials should be detailed in the description of 
treatment packages of investigations concerned with psy-
chotherapy, including the order of administering thera-
peutic components [36]. Citing a published manual or 
adding a supplement containing details can boost the 
probability of attempts to replicate the findings.
Assessment
Psychological assessment blind to treatment assign-
ment has been a cornerstone of psychotherapy research. 
As in double-blind placebo-controlled studies the asses-
sors may recognize patients assigned to medication or 
placebo, also single-blind studies of psychotherapy may 
present with the same problem (e.g., the patient may 
mention the type of treatment he/she is receiving). It is 
also important to assess the patients in a trial not only be-
fore and after treatment but also at some time during fol-
low-up in order to verify long-term outcomes. This is the 
most suitable strategy for differentiating psychopharma-
cological and psychotherapeutic approaches. The follow-
ing issues deserve brief comment.
The term “clinimetrics” [30, 65, 66] indicates a domain 
concerned with the measurement of clinical issues that do 
not find room in customary clinical taxonomy. Such is-
sues include the types, severity, and sequence of symp-
toms; the rate of progression in illness (staging); the se-
verity of comorbidity; problems of functional capacity; 
reasons for medical decisions (e.g., treatment choices), 
and many other aspects of daily life, such as well-being 
and distress. Clinimetrics has a set of rules that govern the 
structure of indices, the choice of component variables, 
and the evaluation of consistency and validity and that 
differ from psychometrics, which was developed outside 
of the clinical field, mainly in the educational and social 
areas. An essential clinimetric requisite for an assessment 
method is its discrimination properties (responsiveness/
sensitivity), which means that it should be able to detect 
clinically relevant changes in health status over time [31]. 
As important is the concept of incremental validity that 
refers to the unique contribution (or incremental in-
crease) in predictive power associated with a particular 
assessment procedure in the clinical decision process 
[30]. Accordingly, each distinct modality of measure-
ment should deliver a unique increase in information in 
order to qualify for inclusion. In clinical research, several 
scales are often used under the misguided assumption 
that nothing will be missed. On the contrary, violation of 
the concept of incremental validity leads to conflicting 
results [30].
In clinical trials priority has been given to the stan-
dardization of observer-rated scales that could be gold 
standards in the differentiation between the efficacy of a 
psychotropic medication compared to placebo. Such 
standardization stems from the necessity of comparing 
studies in different countries which may have different 
languages [31]. As a result, a limited number of symp-
toms is selected and psychological measurements are tar-
geted to test efficacy. These pragmatic needs, however, 
have limited the field and prevented developments. Ex-
cessive reliance on symptoms that are part of diagnostic 
criteria of mental disorders (e.g., major depressive disor-
der and generalized anxiety disorder) has impoverished 
clinical assessment in psychotherapy research and does 
not reflect the broad spectrum of variables that affect 
clinical presentations, such as demoralization and irri-
table mood [2], psychological well-being and euthymia 
[67, 68], mental pain [69], social adjustment and func-
tioning [70–72], illness behavior [2, 73], and patient sat-
isfaction [73]. Patient-reported outcomes [66] are fre-
quently used in psychotherapy research. They may be 
more conservative than clinician-rated outcomes in as-
sessing changes over time [74, 75]. Many self-rating 
scales reflect general aspects of distress and not necessar-
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ily specific treatment targets [76]. Self-rated methods 
might be particularly indicated in the case of computer-
assisted internet-delivered treatments [77]. In child psy-
chotherapy research studies, assessment often includes 
reports from multiple informants [78]. Finally, it is im-
portant to differentiate between outcome and process 
measures.
Another major limitation of standard assessment 
strategies has to do with the fact that targets of assessment 
have predominantly involved the desired effects of a med-
ication. The evaluation of adverse events has been ne-
glected despite the fact that appraisal of side effects of psy-
chotherapy has attracted increasing interest [79, 80]. Psy-
chotherapists are biased against recognizing their own 
treatment’s side effects [79]. The assessment of side ef-
fects of psychotherapy entails a number of problems: side 
effects may be related not only to symptoms or course of 
illness but also to other areas in life, and it is difficult to 
ascertain the relationship between a certain event and a 
treatment. As with adverse events induced by medica-
tions, recognition of side effects depends on the adequacy 
of collection strategies [79, 80], and both interviews and 
self-rated instruments can be used. 
Outcome Determination
It has become common practice in RCT to quantify 
the number of participants who, after a pharmacologic 
and/or psychotherapeutic trial, achieve response or re-
mission according to specific cutoff points of rating 
scales [12, 14, 62]. Remission can be expressed either as 
a categorical variable (present/absent) or as a compara-
tive category (nonrecovered, slightly recovered, moder-
ately recovered, or greatly recovered) which refers to the 
clinical distance between the current state of the patient 
and his/her pretreatment position [81]. In the same 
vein, many studies are concerned with relapse and re-
currence as primary outcome measures, even though 
adequate criteria are not available for all mental health 
conditions. It is important, however, to indicate the 
number of participants who display deterioration after 
treatment according to specific cutoff points of the same 
rating scales [36]. In fact, in clinical trials where differ-
entiation according to cogent subgroups is made, a 
treatment which is helpful on average may be ineffective 
in some patients (no difference with placebo) and even 
harmful in someone else (worse than placebo) [7, 82]. 
The same phenomena have been described with the out-
come of psychotherapy [8].
Further, including biomarkers as secondary outcomes, 
in addition to the primary outcome that is used in any 
psychotherapy trial, may be particularly helpful. Exam-
ples of biomarkers may encompass changes in neuro-
trophins such as BDNF, neuroimaging changes after psy-
chological intervention, or digital biomarkers such as ac-
tigraphy [68, 83]. Big data approaches may open new 
avenues in psychotherapy research through behavioral 
biomarkers [84].
Table 1. Methodological recommendations for randomized con-
trolled trials of psychological interventions
1 In addition to the cross-sectional assessment of the DSM-5, 
the longitudinal development of the disorder (acute, 
residual, chronic, etc.) should be described according to 
staging methods.
2 Current or past treatment with psychotropic medications 
needs to be detailed, specifying the medications that were 
involved; staging methods may be used.
3 In parallel treatment designs, the limitations of the use of 
waiting list or treatment as usual or other treatment control 
groups should be acknowledged; “attention placebo” and 
“clinical management” provide more reliable control groups, 
as long as the patient receives the same amount of time and 
attention from a professional figure that occurs with the 
experimental group (without any specific interventions).
4 Adaptive and dismantling designs may provide valuable 
insights into the incremental role of psychological 
interventions.
5 All potential treatment ingredients that were found to yield 
significant effects in controlled trials should be detailed in 
the description of psychological treatments, including the 
order of administration of therapeutic components.
6 Assessment should be performed under blind conditions not 
only before and after treatment but also at some time during 
follow-up to verify long-term outcomes. 
7 Each distinct modality of measurement should deliver a 
unique increase in information in order to qualify for 
inclusion (incremental validity).
8 A combination of observer- and self-rated tools (patient-
reported outcome measures) is recommended.
9 Assessment of side effects of psychotherapy should be 
performed using suitable methods of evaluation.
10 The number of participants who display deterioration after 
treatment according to the methods that were used for 
defining response or remission should be indicated.
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Conclusions
The main methodological recommendations that we 
have discussed are summarized in Table 1. Psychothera-
py research has produced major clinical advances in the 
treatment of mental disorders. The question is how to put 
the available evidence within the context of individual 
unique assets and liabilities. The methodological innova-
tions that we have outlined may demarcate major prog-
nostic and therapeutic differences in psychological trials 
and yield valuable insights into the clinical role of psycho-
therapy. 
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